Three trends LeadsRx predicts will rock the marketing attribution landscape

PORTLAND, OR / ACCESSWIRE / December 17, 2019 / Marketing attribution is poised for a challenging leap in 2020. The innovators and early adopters have been feasting, optimizing return on ad spend (ROAS) by deploying sophisticated universal tracking and multi-touch technologies.

The competition is catching up. In 2020, marketing attribution will cross the chasm into widespread adoption. As the industry jumps forward, marketing attribution software company LeadsRx is looking into its impartial multi-touch attribution crystal ball to identify three challenging trends that will separate winning marketers from those who get left behind:

Virtual is Reality

LeadsRx prediction for marketing executives: In 2020 courageous marketers need to factor in virtual assisted technologies and how they are impacting their understanding of the customer journey. Those who prepare will reap the significant ROAS opportunities; those who don't will experience a growing blind spot in their marketing vision.

Virtual assistants – including intelligent chatbots and other forms of artificial intelligence (AI) – will play a vital role in the customer journey. In the next five years, AI is expected to manage 70 percent to 90 percent of all initial customer interactions. Marketers who aren't including this important touchpoint in their attribution modeling stand to lose out on critically important insights.

The rapid adoption of AI technologies, coupled with the high level of trust they've engendered in both buyers and sellers, has elevated virtual assistants (VA's) well beyond the role of menial task managers. VA's now provide critical touchpoints in the customer journey.

In the automotive industry, intelligent chatbots are motivating online shoppers to visit showrooms, leading to vehicle sales. The chatbot has become a salesperson-initiating conversation, answering questions, building trust-before passing the customer to a human being to complete the transaction.

Layered on top of the VA boom is the increasing use of smart speakers like Amazon Echo and Google Home. Ownership of these devices in the US grew 140 percent from 2017 to 2018. With voice commands, consumers can have an entirely virtual buying experience from start to finish, without the ad views and clicks that marketers rely on.

A Bridge to Streaming

LeadsRx prediction for marketing executives: Embrace customers across all broadcast mediums to build long lasting relationships. Success requires employing universal tracking technologies that bridge across streaming platforms spanning TV, radio, podcasts and mobile gaming.

As the streaming audience surpasses many traditional channels, universal tracking technologies need to span and incorporate systems like addressable TV and streaming radio.

An estimated 3.5 million households cut the cord on pay TV last year, underscoring a clear message from consumers: they want their content when they want it, where they want it. As a result, a higher percentage of US households now have a video streaming subscription than have a pay TV subscription.

Those households are creating a la carte solutions, subscribing to an average of three video streaming services to get the features they value most. More than half of Millennials and Gen Z consumers also subscribe to streaming services for music and gaming.

This patchwork landscape presents an opportunity for intrepid attribution marketers. Ad spend on streaming services increasingly requires a tactical and targeted approach, as consumers have cited ad load as a major reason for turning away from traditional channels.

A recent study indicates that viewers have a maximum tolerance of sixteen minutes of ads per hour, with a Goldilocks target of eight minutes. Traditional pay TV peaks at roughly twenty minutes of advertising per hour. In addition to the time threshold, viewers are particularly turned off by frequent repetition of the same ads.

Radio Sets the Tone

LeadsRx prediction for marketing executives: The radio industry's pervasive success using marketing attribution set a benchmark and major brands are reaping the rewards. In 2020, there will be a marked increase in the number global and local brands and agencies applying the same techniques to their digital spend and arming themselves with attribution data that can be easily communicated to C-level executives in a compelling, relatable manner.

The radio industry's dominant use of marketing attribution to track conversions and web lift will spread into mainstream adoption, likely triggering a tipping point for all mediums including digital, direct mail, telemarketing, out-of-home, and more. A recent joint study from iHeartMedia and LeadsRx on the Five Secrets for Automotive Advertising showcases how smart advertisers are leveraging attribution to optimize ad campaigns on radio.

The coming year will no doubt spark innumerable conversations about the digital-first mindset, the Internet of Things and the emergence of any number of new technologies. Easy in that environment for marketers to fall into a herd mentality, placing their ad faith-and budget-in Facebook, Google and Instagram.

In 2020, data-driven marketers will be wise to break from the herd and model an unlikely trendsetter: radio. The industry has been dominant in recent years in the use of attribution to build transparency and accountability into their advertising. Nearly all major radio broadcasters now offer attribution insights as part of their selling team's toolset making this pervasive use a de facto standard.

Our joint 2019 Attribution Marketing study of direct-to-consumer (D2C) brands with broadcaster Westwood One found that on average, advertising on radio drove a 21 percent increase in shoppers on their websites. That's comparable to Google/Facebook, more than 17 percent, and TV, greater than 19 percent, but with significantly lower investment, yielding a much higher ROI for radio.

The message to marketing executives is not that radio is effective, it's that radio can prove that it's effective through impartial, multi-touch attribution. Until recently, radio didn't have that capability, and advertisers favored digital ads simply because the results could be measured, not because the ads were more effective. With accurate, insightful attribution, many big advertisers have moved back into radio.

About LeadsRx

A fast innovator and a marketer's choice for 3,000-plus global and local brands, LeadsRx is an unrivaled multi-touch attribution SaaS platform. Powered by a unique Universal Conversion Tracking Pixel, LeadsRx provides an impartial view of customer journeys, giving each advertising touchpoint proper weight and credit including broadcast media. Founded by marketers, LeadsRx enables companies of any size to elevate marketing performance in a framework that is easily understood delivering sustainable return on ad spend (ROAS). To learn more about how LeadsRx can support you in marketing transformation visit LeadsRx.com. Connect with LeadsRx on Twitter, LinkedIn and Facebook.

For more information

Jeff Fishburn
Fishburn PR for LeadsRx
+1 (503) 799-1988
jeff@fishburnpr.com

SOURCE: LeadsRx

ReleaseID: 570270

CCC has been awarded recognition as "Leading Pioneers in Medical Marijuana Registration – Pennsylvania" : Distinction Award for Cannabis Medicine Advancement 2020 by Global Health and Pharma's International Medical Marijuana Awards 2019

PITTSBURGH, PA / ACCESSWIRE / December 17, 2019 / COMPASSIONATE CERTIFICATION CENTERS™, ™ (www.CCCregister.com), a first of its kind medical cannabis healthcare system, announces recognition and award as "Leading Pioneers in Medical Marijuana Registration – Pennsylvania

Distinction Award for Cannabis Medicine Advancement 2020" by GHP (Global Health & Pharma) in the International Medical Marijuana Awards 2019.

Collectively, the Global Health and Pharma Awards span numerous markets across the Human, Animal, and Environmental Health fields. The prestigious awards are based on merit and research done by GHP's team. This is the first year GHP has included an awards presentation for Medical Marijuana businesses. "We were thrilled when GHP contacted us to let us know we had been nominated for one of the very first GHP Medical Marijuana Awards. This recognition proves that CCC has and continues to make incredible strides for both patients and non-cardholders, most prominently in the Pennsylvania market."

Compassionate Certification Centers was evaluated by GHP board members based on accomplishments, future projects, patient feedback, and values amongst other criteria. Winners were chosen based on merit and not votes from the public. The award for "Leading Pioneers in Medical Marijuana Registration – Pennsylvania Distinction Award for Cannabis Medicine Advancement 2020" showcases the company's prominence as the state's first Certification Center, as well as its role in the advancement of cannabis medicine and research.

About Compassionate Certification Centers

Compassionate Certification Centers is the first U.S. Medical Cannabis Healthcare System, specializing in cannabis medicine. The company is devoted to assisting U.S. citizens with discovering cannabis-derived treatment options for a wide-range of medical conditions.

Compassionate Certification Centers' network of convenient healthcare centers operate throughout some of the top U.S. medical regions providing Medical Marijuana consultations, THC & CBD treatment plans, and High-Quality CBD products. Recently, the company has announced their participation in efforts to further expand medical cannabis education and clinical research. For more information on CCC's locations, services, or products please visit www.CompassionateCertificationCenters.com or call 888-316-9085.

Twitter Facebook LinkedIn

Contact
Melissa Rigby
Melissa@cccenters.org
888-316-9085 | 412-519-5976

SOURCE: Compassionate Certification Centers

ReleaseID: 570390

This News Release is Intended for Distribution in Canada Only

Not for Distribution to U.S. Newswire Services or for Release, Publication, Distribution or Dissemination Directly, or Indirectly, in Whole or in Part, in or Into the United States

TORONTO, ON / ACCESSWIRE / December 17, 2019 / EQ Inc. (TSXV:EQ) ("EQ Works" or the "Company"), a leader in delivering location behavioural data and intelligence, is pleased to announce that due to increased demand for its previously announced non-brokered private placement, press released on December 10, 2019, the Company has increased the size of the private placement (the "Private Placement"), resulting in aggregate gross proceeds of $5 million. On December 17, 2019, the Company completed a second and final tranche of 564,836 units ("Units") at a price of $0.75 per Unit for aggregate gross proceeds of $423,627.

In total, the Private Placement consisted of 6,666,666 Units, with each Unit being comprised of one common share in the capital of the Company (a "Common Share") and one-half of one common share purchase warrant (each full warrant, a "Warrant"). Each Warrant is exercisable at a price of $1.00 per Common Share, for a period of 24 months following the closing of the Private Placement. The expiry date of the Warrants may be accelerated by the Company at any time if the closing price of the Common Shares on the facilities of the TSX Venture Exchange (the "TSX-V") is greater than $1.25 for any 10 consecutive trading days following the date that is four months and one day after the closing of the Private Placement.

The proceeds of the Private Placement are expected to enable the Company to continue building its data platform, developing its data science practice and further expanding into the U.S.

In connection with the Private Placement, the Company paid aggregate finders fees of $26,170 in cash and issued 34,893 finder warrants on the same terms as the Warrants.

Pursuant to applicable securities laws, the securities issued under the Private Placement are subject to a hold period for four months and one day from the closing of the Private Placement, expiring April 18, 2020. The Private Placement remains subject to the final acceptance of the TSX-V.

About EQ Works

EQ Works (www.eqworks.com) provides a smarter way to target customers. Using first-party, location-based behaviour signals, advanced data analytics, and proprietary software, EQ Works creates and targets customized, performance-boosting audience segments. Proprietary algorithms and data generate attribution models that connect consumer behavior in the physical world to consumer behavior in the digital world, solving complex challenges for brands and agencies.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking statements, which may include, without limitation, statements with respect to the use of proceeds from the Private Placement, the Company's ability to continue building its data platform and to develop data science practices, and the Company's expansion into the United States. The forward-looking statements are based on management's current expectations and/or assumptions, and are subject to known and unknown uncertainties and risks, which could cause actual results to differ materially from those contemplated or implied by such forward-looking statements. When used in this press release, the words "estimate", "project", "belief", "anticipate", "intend", "expect", "plan", "predict", "may" or "should" and the negative of these words or such variations thereon or comparable terminology are intended to identify forward-looking statements.

By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among other things, the demand for EQ Works' products and services; a history of net losses; restructuring; intellectual property actions; credit risk from trade credit; changing nature of internet and mobile advertising; failure of real-time advertising exchanges to attract publishers; government regulation of the internet; system failures; competition from new customers and products; rapid technological change; lengthy sales cycles hindering adoption of EQ Works' solutions; third-party claims related to content in advertising delivered by EQ Works; as well as those factors disclosed in the Company's publicly filed documents. This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company's forward-looking statements. The Company undertakes no obligation to update any forward-looking statements (unless required by law) contained herein should material facts change due to new information, future events or otherwise.

EQ Inc.
1235 Bay Street, Suite 401| Toronto, Ontario |M5R 3K4
p: 416.597.8889
press@eqworks.com
www.eqworks.com
Contact: Peter Kanniah, Chief Financial Officer

SOURCE: EQ Inc.

ReleaseID: 570505

Grid to Present at PDAC 2020 Nickel and PGM Session

TORONTO, ON / ACCESSWIRE / December 17, 2019 / Grid Metals Corp (TSXV:GRDM) "Grid" or the "Company" is pleased to announce that it will be presenter at the Nickel and PGM Session at the 2020 Prospectors and Developers Conference in Toronto. The Grid presentation will take place on March 3, 2020 at 10:45:00 AM in Room 801B in the Metro Toronto Convention Centre, South Building. The Company presentation will review the latest developments at the PEA stage Makwa Mayville Nickel Copper PGM Project located in Manitoba and the exploration stage East Bull Lake PGM Property located 80 km west of Sudbury ON.

Financing Extension

The Company has received approval of the TSXV to extend the closing date of the non- brokered private placement of up to $500,000 announced on October 29, 2019 ( the "Offering") . The Offering consists of a Hard Dollar Offering ( a $0.10 Unit comprised of one common share and one common share warrant exercisable at $0.15 for two years) and a Flow Through Offering of flow through common shares at a price of $0.125 per share. To date a total of $285,000 has been closed.

The financing has been extended until January 13, 2020. The Offering is subject to an over allotment option of 25% in the discretion of the Company

About Grid Metals Corp.

Grid Metals Corp. is an exploration and development Company that has a diversified portfolio of projects in the nickel-copper-platinum group metal sectors. These commodities are vital to the emerging battery metals, energy storage and automotive sectors. All of Grid's projects are located in secure North American mining jurisdictions. The Company is focused on timely advancement of its property portfolio through prudent exploration and development activities.

In addition to the East Bull Lake PGM Property Grid has ongoing development work at its Makwa Mayville Nickel-Copper-PGM project located in Manitoba. The Company has ongoing work being completed towards completion of an updated NI 43-101 Preliminary Economic Assessment (PEA) of that project. The existing PEA was completed in April 2014.

To find out more about Grid Metals, please visit www.gridmetalscorp.com.

On Behalf of the Board of Grid Metals Corp.

Robin Dunbar – President, CEO & Director
Telephone: 416-955-4773
David Black – Investor Relations
Email: rd@gridmetalscorp.com
Email: info@gridmetalscorp.com

We seek safe harbour.

This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of the Securities Act (Ontario) (together, "forward-looking statements"). Such forward-looking statements may include the Company's plans for its properties, the overall economic potential of its properties, the availability of adequate financing and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements expressed or implied by such forward-looking statements to be materially different. Such factors include, among others, risks and uncertainties relating to potential political risk, uncertainty of production and capital costs estimates and the potential for unexpected costs and expenses, physical risks inherent in mining operations, metallurgical risk, currency fluctuations, fluctuations in the price of nickel, cobalt, copper and other metals, completion of economic evaluations, changes in project parameters as plans continue to be refined, the inability or failure to obtain adequate financing on a timely basis, and other risks and uncertainties, including those described in the Company's Management Discussion and Analysis for the most recent financial period and Material Change Reports filed with the Canadian Securities Administrators and available at www.sedar.com.

Neither the TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to the account or benefit of a U.S. person absent an exemption from the registration requirements of such Act.

SOURCE: Grid Metals Corp

ReleaseID: 570465

NEW YORK, NY / ACCESSWIRE / December 17, 2019 / Since 2018, Agara has handled over half a million consumer support emails for Procter & Gamble, an American multinational consumer goods corporation, improving its query handling efficiency by over 30% while delivering a better consumer experience, and improved quality scores. P&G intends to expand the success to phone support calls using Agara's state-of-the-art Real-time Voice AI system to provide highly contextual suggestions to advisers in real-time.

Being one of the few platforms that can handle live phone calls, Agara combines 14 Deep Learning modules to suggest the best actions to handle consumer queries and reduce the number of screens an adviser must deal with to one – often reducing it from as high as nine. The Real-time Voice AI handles speech-to-text conversion, recognizes intents, detects consumer's emotional state, extracts information from the discussion and navigates a myriad of IT systems to help the adviser with what they should respond, gives them the information they need, shows them the consumer's details, and guides them through company policies. Agara's solution drives a significant difference in an industry where human-centric consumer service can be re-oriented to its original and most important purpose, which is actively listening and mastering the consumer conversation, enhanced by the power of AI.

Trained on more than 3 million consumer support queries and 60,000 hours of consumer support calls, the Real-time Voice AI can handle hundreds of calls simultaneously and instantly, while integrating the human adviser in the process. This is a huge assistance not only for advisers during holiday seasons and support volume spikes (where abandoned calls in this industry can climb up to 80% in average), but also for the general brand image, as dissatisfied consumers quickly share their negative views on social media.

Agara, which raised over $3M in venture capital from Kleiner Perkins, Blume Ventures and RTP Global, has helped over 300 advisers for 60+ brands serve more than 1 million consumers in 6 countries and 2 languages in the past 12 months. This number is expected to grow as global expansion across P&G markets and languages continues to expand rapidly in the next year.

P&G is deploying Agara across its US and Canada call centers in a phased manner. Upon full rollout, the system will be assisting with over a million phone calls each year.

Rosa Maria Cruz, P&G Global Consumer Relations Americas leader and Global CIO stated, "Agara's partnership has been strategic in our vision of creating delightful P&G consumer experiences, where Augmented Intelligence gifts our advisers with "super-powers", allowing them to focus on building trusted consumer relationships at scale that bring to life the superiority of our brands and products, touching and improving our consumers' lives".

Abhimanyu, founder and CEO of Agara said, "The implementation of Agara's Real-time Voice AI at P&G is the largest implementation of its kind in the world. It is also the first major milestone in the journey towards a voice-first interface that Agara is building for business-to-consumer communication. Our next milestone would be the rollout of the world's first fully autonomous Conversational Voice AI which will set the standards for future bots".

Media contact:
Rodney Goedhart
rodney.goedhart@innowire-advisory.com
1-619-940-1412

SOURCE: Agara

ReleaseID: 570406

VANCOUVER, BC / ACCESSWIRE / December 17, 2019 / Cielo Waste Solutions Corp. (CSE:CMC – OTCQB:CWSFF) ("Cielo" or the "Company") is pleased to announce the appointment of Lionel Robins to the Board of Directors of Cielo.

Mr. Robins is a serial entrepreneur residing in Grande Prairie, Alberta. Mr. Robins is actively involved in the local community and is the principal of a number of local businesses, including a trucking company, five car-dealerships and a real-estate company that collectively employs approximately 200 individuals. Mr. Robins currently sits on the Board of Directors of STARS Air Ambulance and is the Chairman of their Foundation Committee, tasked with heading up an aggressive $110 million CAD capital fundraising project to replace their entire helicopter fleet across Alberta, Saskatchewan and Manitoba. Mr. Robins also served as Chair of the 2018 Alberta Summer Games after leading a successful bid to host the 2018 Games in Grande Prairie, Alberta.

Mr. Robins is also a co-founder and the CEO of Renewable U Energy Inc., which has entered into four memorandums of understanding with Cielo, directly or through its subsidiaries, ("Renewable U Companies") to build green joint venture renewable diesel fuel refineries ("JV Refineries") in Grande Prairie, Brooks, Medicine Hat and Lethbridge, Alberta ("Joint Ventures"). The Renewable U Companies have advanced $1 million CAD to date to Cielo and have agreed to pay 100% of the costs, as well as a 7% management fee to Cielo to build the first JV Refinery in each territory at an estimated cost of approximately $50 million CAD per refinery (increased from the previously anticipated cost of $20 million CAD per JV Refinery as a result of the revised plans to increase the scale and output to 4,000 liters per hour). Each JV Refinery is expected to employ approximately 50 people during the construction and commissioning stages and will be engineered to produce about 32 million litres a year of renewable fuels.

Mr. Robins commented, "I am honored to be invited to join Cielo's Board of Directors and look forward to assisting Cielo in deploying its proprietary technology first in Alberta and then worldwide."

Don Allan, Cielo's President and CEO, stated, "Cielo's management and board welcomes Mr. Robins to our Board of Directors. Having worked closely with Lionel over the past 14 months, we are confident that his business acumen and network of like-minded, environmentally conscious people will help us to grow our company and deploy our green technology around the world."

FINRA has issued Cielo a new trading symbol more in line with the Company's name. The new trading symbol is CWSFF, which replaces the previous symbol CEIWF. Effective as of the opening of the OTCQB market on December 17th, 2019, Cielo will be trading under its new symbol.

Cielo is also pleased to announce that The Weather Network has created a video from a recent interview with Cielo's President and CEO, Don Allan, which is now accessible on their website – www.theweathernetwork.com. The video, featuring Cielo's proprietary, green, waste to high-grade renewable diesel refinery solution, is also being played periodically on The Weather Network's cable television channel (https://www.theweathernetwork.com/ca/news/article/calgary-company-transforms-garbage-into-renewable-diesel).

Mr. Don Allan, President and CEO of Cielo, further comments: "We are extremely pleased with the media attention that Cielo is receiving. We believe the green technology that we are working towards commercializing globally has the potential to make the planet a better place for generations to come. Cielo's business model is to build one of the greenest public company possible. One of the benefits of Cielo being a public company is to be able to provide an opportunity to individuals and corporations from around the world to be able to participate in our goal of reducing the amount of waste that goes into landfills.

Join Cielo shareholders on 8020 Connect: http://connects.digital/cielo1

On behalf of the Board of Directors of the Company,

Don Allan, President / CEO / Director

Cielo Waste Management Corp.

Investor Contacts

Renewable U Energy Inc. RB Milestone Group, LLC
Lionel Robins, CEO Trevor Brucato, Managing Director
Lionel@RenewableU.ca New York, NY & Stamford, CT
tbrucato@rbmilestone.com

SOURCE: Cielo Waste Solutions Corp.

ReleaseID: 570514

Animal Health Industry Veteran Will Strengthen Management Team as MYOS Expands Its Veterinary Business in 2020

CEDAR KNOLLS, NJ / ACCESSWIRE / December 17, 2019 / MYOS RENS Technology, Inc. ("MYOS" or "the Company") (NASDAQ:MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition made from fertilized egg yolk that helps build lean muscle, announced today that Albert Ahn, DVM has joined MYOS as a Strategic Adviser to guide the development and expansion of its animal health business of Fortetropin-based canine muscle health formulas. Dr. Ahn is a veteran of the Animal Health Industry with over 25 years of industry experience, including roles as President at AB Science, USA, a canine oncology company; Chief Scientific Officer at Summit VetPharm, a division of Sumitomo Corporation of America, in addition to roles at Hill's Pet Nutrition. Dr. Ahn's accomplishments include developing the marketing strategy for Heartgard® Plus, the blockbuster heartworm disease prevention product while serving at Boehringer Ingelheim and bringing Vectra 3D®, a next-generation product for flea and tick control, to market during his tenure with Sumitomo.

"We are delighted that Dr. Ahn has joined MYOS as a Strategic Adviser to the Company," stated Joseph Mannello, CEO of MYOS. "We believe Dr. Ahn's experience in animal health, product development, and launch will strengthen MYOS Canine Muscle Health Formula®'s ("Myos Canine") reach in the pet industry, which has been experiencing explosive growth—there are over 90 million dogs in the U.S. alone, with over 70 million being seen by veterinarians on a regular basis. Our pets are living longer and quality-of-life issues pertain to them as well as humans—our canine product addresses muscle health, improving the odds for canines that live longer, to have a better chance of living better into their golden years. Dr. Ahn will help us in the veterinary channel with his strong relationships with key opinion leaders, veterinary colleges, distributors and his peers. We are now poised to build a world-class animal health business," added Mr. Mannello.

"I am delighted to join MYOS as a Strategic Adviser," stated Dr. Ahn. "The Company has truly remarkable potential to address both animal and human muscle health through its innovative nutrition products. Very few nutrition companies, particularly of this size, have completed the degree of clinical research that MYOS has completed on Fortetropin. Veterinarians are increasingly becoming aware of the importance of managing sarcopenia in animals in order to positively impact the quality of their lives. MYOS' products provide the potential to improve the quality of life for both man and man's best friend," added Dr. Ahn.

"This past year was a transformative year for MYOS, overall, and specifically for our animal health business, as we obtained positive results on Fortetropin from a veterinary clinical study at Kansas State University. In addition to establishing distribution for our branded MYOS Canine product with Amazon and Chewy.com, we have experienced strong sales growth from MYOS Canine since its launch in 2018, along with a groundswell of loyalty among pet owners and veterinarians across the United States. This is evidenced by the dozens of heartwarming testimonials that we receive every week from our customers," concluded Mr. Mannello.

About MYOS RENS Technology Inc.

MYOS RENS Technology Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition company that develops and markets products that improve muscle health and performance. MYOS is the owner of Fortetropin®, a fertilized egg yolk-based product manufactured via a proprietary process to retain and optimize its biological activity. Fortetropin has been clinically shown to increase muscle size, lean body mass and reduce muscle atrophy. MYOS believes Fortetropin has the potential to redefine existing standards of physical health and wellness. For more information, please visit www.myosrens.com.

About Myos Canine Muscle Formula®

Myos Canine Muscle Formula (Regular and Veterinarian Strength) is an advanced veterinary health supplement to support muscle health in dogs, featuring Fortetropin as the active ingredient. Fortetropin is made through a patented process that maintains the vital nutrients of fertilized egg yolks to help build more lean muscle and decrease muscle loss. For more information, please visit www.myospet.com.

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful results of strategic initiatives, the success of our products, including Qurr®, Yolked®, MYOS Canine Muscle Formula®, Physician Muscle Health Formula® and MYOS Enteral Nutrition Formula™, the success of our research and development, the results of the clinical evaluation of Fortetropin® and its effects, the ability to enter into new partnership opportunities and the success of our existing partnerships, the ability to generate revenue and cash flow from sales of our products, the ability to increase our revenue and gross profit margins, the ability to achieve a sustainable, profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, the continued listing of our securities on the Nasdaq Stock Market, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

Investor Relations:

Porter LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700
Email: MYOS@plrinvest.com

SOURCE: MYOS RENS Technology, Inc.

ReleaseID: 570452

WALTHAM, MA / ACCESSWIRE / December 17, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or "the Company") announced today that it has received approximately $1.9 million from the exercise of warrants subsequent to the release of positive topline data on November 22, 2019 for its pivotal corneal wound repair study.

The Company is currently evaluating several strategic options in order to determine the best path forward. Following the receipt of warrant exercise proceeds, the Company believes it will have sufficient cash to fund its planned operations through this evaluation process.

In addition, the Company has received the full data package for this study and is now working on the De Novo application. The Company plans to file the application with the FDA for commercialization in the first half of 2020. As previously disclosed, the data did not include any additional efficacy or safety information.

About EyeGate

EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye.

EyeGate's lead product, Ocular Bandage Gel ("OBG"), is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface. EyeGate is in the clinic for two different patient populations: photorefractive keratectomy ("PRK") surgery to demonstrate corneal wound repair and punctate epitheliopathies ("PE"), which includes the treatment of dry eye.

The objective of OBG is to re-epithelialize the cornea, reduce the risk of infection, improve symptoms, and improve ocular surface integrity. Often current treatments fall short as they are ineffective in protecting and enabling corneal re-epithelialization.

If EyeGate receives FDA approval following successful completion of the PRK pivotal study, EyeGate believes OBG will be the only prescription hyaluronic acid eye drop in the U.S. and the only eye drop in the U.S. approved for the healing of corneal epithelial defects. Additionally, if the clinical trials for patients with PE are successful, EyeGate believes OBG will be the only eye drop in the U.S. approved for the treatment of PE.

EGP-437, EyeGate's other product, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through EyeGate's proprietary innovative drug delivery system, the EyeGate II Delivery System.

For more information, please visit www.EyeGatePharma.com.

EyeGate Social Media

EyeGate uses its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter account (https://twitter.com/EyeGatePharma), and LinkedIn page (https://www.linkedin.com/company/135892/) as channels of distribution of information about EyeGate and its product candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor EyeGate's website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate intends to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate's investor relations website.

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the timing of EyeGate's evaluation of strategic options, EyeGate's ability to fund planned operations with cash on hand, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate's products, including EyeGate's OBG product, as well as the success thereof, which approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading "Risk Factors" contained in EyeGate's Annual Report on Form 10-K filed with the SEC on March 1, 2019 or described in EyeGate's other public filings. EyeGate's results may also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Contact

Joseph Green
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030
jgreen@edisongroup.com

SOURCE: EyeGate Pharmaceuticals, Inc.

ReleaseID: 570485

BALA CYNWYD, PA / ACCESSWIRE / December 17, 2019 / Brodsky & Smith, LLC reminds investors of important approaching deadlines regarding class action lawsuits against the following companies for violations of federal securities laws. If you purchased any of the below-listed stocks during the referenced time periods and want to discuss your legal rights, please contact Marc Ackerman, Esquire or Jordan Schatz, Esquire at 877-534-2590. There is no cost or financial obligation to you.

SEALED AIR CORPORATION (NYSE:SEE)

Shares purchased between November 5, 2014 and August 6, 2018

Deadline: December 31, 2019

According to the complaint, throughout the Class Period, the defendants failed to disclose the following adverse facts pertaining to Sealed Air's business, operations and financial condition, which were known to or recklessly disregarded by the defendants: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate the defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating Sealed Air's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.

Additional information can be found at http://www.brodskysmith.com/cases/sealed-air-corporation-nyse-see/, or call 877-534-2590. No cost or obligation to you.

UNDER ARMOUR, INC. (NYSE:UA and UAA)

Shares purchased between August 3, 2016 and November 1, 2019

Deadline: January 6, 2020

According to the complaint, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) Under Armour had been under investigation by and cooperating with the DOJ and SEC since at least July 2017; and (3) as a result, the defendants' statements about Under Armour's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Additional information can be found at http://www.brodskysmith.com/cases/armour-inc-nyse-ua-uaa/, or call 877-534-2590. No cost or obligation to you.

BAXTER INTERNATIONAL (NYSE:BAX)

Shares purchased between February 21, 2019 and October 23, 2019

Deadline: January 24, 2020

According to the complaint, throughout the Class Period, defendants misrepresented and/or failed to disclose that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) Baxter lacked effective internal control over financial reporting; (3) as a result, Baxter's financial statements were misstated and would likely require correction or amendment; (4) due to Baxter's internal investigation, it would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on a Form 10-Q in a timely manner; and (5) as a result of the foregoing, defendants' statements about Baxter's business and operations lacked a reasonable basis.

Additional information can be found at http://www.brodskysmith.com/cases/baxter-international-nyse-bax/, or call 877-534-2590. No cost or obligation to you.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

SOURCE: Brodsky & Smith, LLC

ReleaseID: 570423